Table 1.
Demographic and Tumor Characteristics for Patients With NMIBC (N = 3,466)a
| Characteristic | Without prior radiation therapy (n = 3,321) | With prior radiation therapy (n = 145) | P value |
| Age, y | 75.0 (71.0-80.0) | 77.0 (73.0-82.0) | <.001 |
| Race and ethnicity | .16 | ||
| White | 3,128 (94.2) | >123 (>84.8) | |
| Black | 60 (1.8) | <11 (<7.6) | |
| Otherb | 110 (3.3) | <11 (<7.6) | |
| Unknown | 23 (0.7) | 0 (0.0) | |
| Married | 2,424 (77.3) | 103 (76.9) | .91 |
| Median income for zip code (×$10,000) | 5.2 (3.8-6.9) | 5.7 (4.4-7.1) | .04 |
| Region of patient residence | .08 | ||
| Midwest | 345 (10.4) | 15 (10.3) | |
| Northeast | 790 (23.8) | 45 (31.0) | |
| South | 816 (24.6) | 24 (16.6) | |
| West | 1,370 (41.3) | 61 (42.1) | |
| Rural-Urban Continuum Code | (n = 3,320) | .26 | |
| Metropolitan counties | 2,768 (83.4) | 126 (86.9) | |
| Nonmetropolitan counties | 552 (16.6) | 19 (13.1) | |
| Comorbid conditions | |||
| History of myocardial infarction | 129 (3.9) | <11 (<7.6) | .88 |
| Peripheral vascular disease | 407 (12.3) | 22 (15.2) | .30 |
| Diabetes | 882 (26.6) | 40 (27.6) | .78 |
| Moderate to severe kidney disease | 200 (6.0) | 16 (11.0) | .01 |
| Charlson Comorbidity Index score | .13 | ||
| 0-1 | 2,469 (74.3) | 97 (66.9) | |
| 2-3 | 645 (19.4) | 36 (24.8) | |
| ≥4 | 207 (6.2) | 12 (8.3) | |
| AJCC T stage | .002 | ||
| Ta | 1,359 (40.9) | 65 (44.8) | |
| Tis | 359 (10.8) | 27 (18.6) | |
| T1 | 1,603 (48.3) | 53 (36.6) | |
| Grade | .63 | ||
| Low Grade | 836 (30.5) | 30 (28.3) | |
| High Grade | 1908 (69.5) | 76 (71.7) | |
| Tumor histologic findings | .75 | ||
| Unspecified neoplasms | <11 (<0.3) | 0 (0.0) | |
| Epithelial neoplasms | 34 (1.0) | <11 (<7.6) | |
| Squamous cell neoplasms | 14 (0.4) | 0 (0.0) | |
| Transitional cell carcinomas | >3,240 (>97.6) | >134 (>92.4) | |
| Adenomas and adenocarcinomas | <11 (<0.3) | 0 (0.0) | |
| Cystic, mucinous, and serous neoplasms | <11 (<0.3) | 0 (0.0) | |
| BCG treatments within 1 y after bladder cancer diagnosis, No. | 9.0 (8.0-12.0) | 10.0 (9.0-12.0) | .42 |
| BCG treatments > 1 y after bladder cancer diagnosis, No. | 6.0 (3.0-10.0) | 6.0 (3.0-10.5) | .70 |
| Time from bladder cancer diagnosis to earliest BCG treatment within 1 y after bladder cancer diagnosis, d | 59.0 (42.0-90.0) | 58.0 (39.0-89.0) | .80 |
| TURBT after bladder cancer diagnosis at 5-y follow-up visit, No. | 3.0 (2.0-4.0) | 3.0 (2.0-5.0) | .14 |
Abbreviations: AJCC, American Joint Committee on Cancer; BCG, bacille Calmette-Guérin; NMIBC, non–muscle-invasive bladder cancer; TURBT, transurethral resections of bladder tumor. aData are number (%) or median (IQR). Specific numbers fewer than 11 cannot be reported according to requirements from Surveillance, Epidemiology, and End Results. bOther race includes American Indian/Alaska Native and Asian/Pacific Islander.